clinical trial · NCT07223502
A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease
Sarfez Pharmaceuticals, Inc.·phase3·recruiting·n = 30
Hypertension (HTN)Combination Product: FDC of spironolactone and ER torsemideCombination Product: Stabilized doses of loop diuretic and finerenone
brief summary
A study Comparing the Clinical Benefit of Finerenone Versus a Fixed-Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients with Hypertension and Chronic Kidney Disease.
started
Dec 1, 2025
primary completion
Jul 1, 2026
completion
Oct 1, 2026
last updated
Mar 9, 2026
detailed description
SAR-ERTSP-01P, A Randomized, Parallel, Two-Arm Study Comparing the Net Clinical Benefit of Finerenone Versus a Fixed-Dose Combination of Extended-Release Torsemide and Spironolactone in Patients with Hypertension and PRoteinuric ChrOnic KidNey Disease (NEPHRON).
official title
A Randomized, Parallel, Two Arm Study Comparing the Net Clinical Benefit of Finerenone Versus a Fixed Dose Combination of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and PRoteinuric ChrOnic KidNey Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol